Neuromyelitis Optica Spectrum Disorder (NMOSD)
Home / Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis Optica Spectrum Disorder (NMOSD)
NMOSD is a rare, antibody-mediated disorder often mistaken for MS. It is associated withantibodies against aquaporin-4 (AQP4). FDA-approved targeted therapies include:
- Eculizumab (Soliris®) – complement inhibition
- Inebilizumab (Uplizna®) – B-cell depletion
- Satralizumab (Enspryng®) – IL-6 receptor inhibition
These agents have dramatically reduced relapse rates and disability progression.
Your Financial Contribution Can Help Us Fund Critical Programs & Initiatives
As a Nonprofit organization, we are deeply committed to raising awareness, providing patient support, and advocating for research for individuals living with various disease states.
Quick Links
Rare Diseases
Contact Us
For general questions about our organization, our mission, or how you can get involved, please email us. We endeavor to respond to all inquiries